Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NICE blocked on breast cancer ruling

OXFORD - Although Britain's National Institute for Clinical Excellence (NICE) last week was able to render a positive recommendation to the U.K.'s National Health Service about the use of Taxol paclitaxel in ovarian cancer, it was blocked from announcing its verdict on the use of taxanes for breast cancer.

Four-fifths of the 4,000 breast cancer patients in England and Wales who would benefit from the taxanes are denied them by the health authority. It is rumored that NICE was willing to recommend the use of Aventis S.A.'s

Read the full 861 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE